Clinical trial
Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis
NCT00432406 · Chinese University of Hong Kong, Other · Completed
Key facts
| NCT number | NCT00432406 |
|---|---|
| Title | Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis |
| Official title | TNF-α Blockade for Psoriatic Arthritis - A Clinical and MRI Study, and the Effects on Cytokine and Cardiovascular Risk Profile |
| Lead sponsor | Chinese University of Hong Kong, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Psoriatic Arthritis |
| Intervention type | Drug |
| Interventions | Infliximab, Etanercept |
| Enrollment | 40 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Feb 7, 2007 |
| Last update posted | Mar 11, 2009 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: